OptimizeRx Corporation
OPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $26 | $29 | $22 | $32 |
| % Growth | -10.7% | 33.1% | -32.1% | – |
| Cost of Goods Sold | $9 | $11 | $9 | $10 |
| Gross Profit | $18 | $19 | $13 | $22 |
| % Margin | 67.2% | 63.8% | 60.9% | 68.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $14 | $14 | $14 | $17 |
| SG&A Expenses | $14 | $14 | $14 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Expenses | $15 | $15 | $15 | $18 |
| Operating Income | $2 | $3 | -$2 | $4 |
| % Margin | 7.9% | 10.9% | -9.6% | 11.2% |
| Other Income/Exp. Net | -$1 | -$1 | -$1 | -$1 |
| Pre-Tax Income | $1 | $2 | -$3 | $2 |
| Tax Expense | $0 | $0 | -$1 | $2 |
| Net Income | $1 | $2 | -$2 | -$0 |
| % Margin | 3% | 5.2% | -10% | -0.2% |
| EPS | 0.04 | 0.083 | -0.12 | 0 |
| % Growth | -51.7% | 169% | – | – |
| EPS Diluted | 0.04 | 0.081 | -0.12 | 0 |
| Weighted Avg Shares Out | 19 | 19 | 18 | 18 |
| Weighted Avg Shares Out Dil | 19 | 19 | 18 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $2 | $1 | $2 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $3 | $4 | -$1 | $5 |
| % Margin | 12.1% | 15% | -4.1% | 15.1% |